secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-028993
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q4 DEXTENZA rev $13.9M (+14% YoY); guides 2023 rev $55-60M; net loss $71M
--------------------------------------------------------------------------------

- DEXTENZA net product revenue Q4 2022 $13.9M (+14% YoY, +17% QoQ); full year $50.5M (+20% YoY).
- Total net revenue full year 2022 $51.5M (+18% YoY); net loss $(71.0)M vs $(6.6)M in 2021 (includes $5.2M non-cash item).
- Cash and equivalents $102.3M at Dec 31, 2022; company expects cash runway to mid-2024.
- OTX-TKI Phase 1 wet AMD: 73% rescue-free at 10 months; 92% reduction in treatment burden; pivotal trial planned Q3 2023.
- OTX-TIC Phase 2 glaucoma top-line data expected Q4 2023; Phase 1 diabetic retinopathy trial initiated Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/0001104659-23-028993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/tm238596d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-028993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer